Chemotherapy before and after surgery for high-risk pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- Your care team believes the tumor can be removed with surgery, but it's considered high-risk.
- You have not had any prior treatment for pancreatic cancer.
- You are in reasonably good health, with a performance status of 0 or 1 (meaning you can take care of yourself and are active).
- Your blood counts, liver function, and kidney function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This study compares two different chemotherapy combinations after surgery for pancreatic cancer. The goal is to see which is better at preventing the cancer from coming back. You would receive either liposomal irinotecan with oxaliplatin and S-1, or gemcitabine with capecitabine.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.